GRFS(Grifols, S.A.) 的财务报表:医疗保健,综合制药。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2020-12-31 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $6.15B | $5.82B | $6.38B | $7.16B | $7.79B |
| 毛利润 | $2.60B | $2.32B | $2.33B | $2.70B | $3.02B |
| 营业利润 | $1.15B | $702.18M | $823.85M | $849.37M | $1.29B |
| 净利润 | $712.88M | $222.70M | $194.83M | $45.95M | $169.48M |
| 经营现金流 | $1.28B | $704.44M | −$1.50M | $237.43M | $974.40M |
| 自由现金流 | $956.79M | $412.53M | −$300.33M | −$6.24M | $723.24M |
| 摊薄每股收益 | $1.04 | $0.33 | $0.28 | $0.07 | $0.25 |